{"filing":{"accession_number":"0001999480-26-000016","cik":"0001999480","ticker":"ANRO","company_name":"Alto Neuroscience, Inc.","form":"8-K","filing_date":"2026-05-28","report_date":null,"primary_document":"alto-20260527.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948026000016/alto-20260527.htm"},"events":[{"id":8615,"run_id":7564,"accession_number":"0001999480-26-000016","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Andrew Miller, Ph.D. to the Board of Directors on May 27, 2026, following unanimous Board approval. The disclosure includes detailed biographical information highlighting his extensive biotechnology leadership experience (founder of Karuna Therapeutics, former CEO, COO, and current board member of Kyverna Therapeutics), his compensation arrangements (initial and annual equity grants plus cash retainers), and committee assignments. This is a clear executive appointment event material to investors assessing board composition and governance.","company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","filing_date":"2026-05-28","form":"8-K","submitted_at":null,"items":[{"id":2555,"accession_number":"0001999480-26-000016","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Andrew Miller, Ph.D. to the Board of Directors on May 27, 2026, following unanimous Board approval. The disclosure includes detailed biographical information highlighting his extensive biotechnology leadership experience (founder of Karuna Therapeutics, former CEO, COO, and current board member of Kyverna Therapeutics), his compensation arrangements (initial and annual equity grants plus cash retainers), and committee assignments. This is a clear executive appointment event material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T03:08:47.562261+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2555,"accession_number":"0001999480-26-000016","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Andrew Miller, Ph.D. to the Board of Directors on May 27, 2026, following unanimous Board approval. The disclosure includes detailed biographical information highlighting his extensive biotechnology leadership experience (founder of Karuna Therapeutics, former CEO, COO, and current board member of Kyverna Therapeutics), his compensation arrangements (initial and annual equity grants plus cash retainers), and committee assignments. This is a clear executive appointment event material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T03:08:47.562261+00:00","company_name":"Alto Neuroscience, Inc.","ticker":"ANRO","filing_date":"2026-05-28"}]}